Hepatitis B DNA vaccine - Genexine/Crucell
Latest Information Update: 24 Sep 2007
At a glance
- Originator Genexine
- Class DNA vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 15 Oct 2004 No development reported - Preclinical for Hepatitis B treatment in South Korea (unspecified route)
- 16 Jul 2002 Preclinical trials in Hepatitis B treatment in South Korea (unspecified route)